Last updated 8 days ago
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
500 patients around the world
Available in Puerto Rico, United States, Brazil
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some
of our older studies were sponsored under the name BeiGene, you may see both names used
for this study on this website.
BeOne Medicines
1Research sites
500Patients around the world
This study is for people with
Leukemia
Chronic lymphocytic leukemia
Non-Hodgkin Lymphoma
Small lymphocytic lymphoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 iwCLL criteria.Previously received treatment for CLL/SLL with a covalent Bruton tyrosine kinase inhibitor (cBTKi). Patients should have disease relapsed after or refractory to at least 1 line of therapy including a cBTKi.Participants with SLL must have measurable disease by computed tomography/magnetic resonance imaging, defined as ≥ 1 lymph node > 1.5 cm in longest diameter and measurable in 2 perpendicular diameters.
- Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation.History of known bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention.History of ischemic stroke or intracranial hemorrhage within 6 months before first dose of study drug.Prior exposure to any Bruton tyrosine kinase (BTK) protein degraders or noncovalent Bruton tyrosine kinase inhibitor (ncBTKi).Current or history of central nervous system involvement including the brain, spinal cord, leptomeninges, and cerebrospinal fluid (as documented by imaging, cytology, or biopsy) by CLL/SLL.
Sites
Hospital das Clínicas da FMUSP - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP
Recruiting
SponsorBeOne Medicines
Study typeInterventional
Conditions
Chronic lymphocytic leukemiaSmall lymphocytic lymphoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06973187
